1. The effect of advances in lung-cancer treatment on population mortality;Howlader;N Engl J Med,2020
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.1.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed February 3, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
3. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO Living Guideline, version 2023.1;Singh;J Clin Oncol,2023
4. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC;Herbst;J Thorac Oncol,2021
5. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057);Horn;J Clin Oncol,2017